Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,383Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-82.4EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)22.0Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.9PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M14,400,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IXJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IXJKen Fisher 2016-12-31 Add0.01%$92.39 - $100.8
($96.05)
$ 96.03-0%Add 206.25%54,887
IXJKen Fisher 2016-09-30 Add$99.73 - $105.75
($102.72)
$ 96.03-7%Add 1.69%17,922
IXJKen Fisher 2016-06-30 Add$96.03 - $102.9
($99.72)
$ 96.03-4%Add 45.39%17,624
IXJKen Fisher 2016-03-31 Reduce-0.02%$90.5 - $102.62
($95.44)
$ 96.031%Reduce -86.86%12,122
IXJKen Fisher 2015-12-31 Add0.02%$99.78 - $105.97
($102.96)
$ 96.03-7%Add 380.03%92,228
IXJKen Fisher 2015-09-30 Add$96.45 - $113.73
($107.78)
$ 96.03-11%Add 187.71%19,213
IXJKen Fisher 2015-06-30 Add$107.16 - $112.88
($109.98)
$ 96.03-13%Add 9.14%6,678
IXJKen Fisher 2015-03-31 Reduce$98.86 - $110.66
($104.83)
$ 96.03-8%Reduce -13.27%6,119
IXJKen Fisher 2014-03-31 Buy $84.91 - $93
($89.14)
$ 96.038%New holding5,950
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IXJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


IXJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48912.97view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94466.88view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1756388.24view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.366961.03view
Bebek, IvanDirector 2017-01-16Buy8,990$3.382741.12view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4123321.95view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91244.07view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271431.58view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3859.04view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1563920view

Quarterly/Annual Reports about IXJ:

    News about IXJ:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Why Johnson & Johnson’s 4Q16 Revenues Could Grow Jan 20 2017
    The 'Trump Rally' in Stocks Is Ending -- Here's How You Can Profit Jan 12 2017
    Exploring GlaxoSmithKline’s Business Segments Dec 30 2016
    GlaxoSmithKline’s Revenue Trend Dec 29 2016
    How Does Johnson & Johnson’s Valuation Compare to Its Peers? Dec 09 2016
    Inside Merck’s Business Segment-Wise Performance Dec 01 2016
    Allergan’s Valuation Compared to Its Peers Nov 29 2016
    Inside Eli Lilly’s Neuroscience Franchise Nov 23 2016
    What Can We Expect of Pfizer’s 3Q16 Earnings? Oct 28 2016
    Novartis’s 3Q16 Estimates: How Has Sandoz Performed? Oct 24 2016
    Word on the Street about Merck’s Animal Health Segment Oct 24 2016
    How Did Johnson & Johnson’s Pharmaceutical Segment Do in 3Q16? Oct 21 2016
    Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise Oct 19 2016
    Johnson & Johnson’s Pharmaceuticals Segment: 3Q16 Estimates Oct 14 2016
    AstraZeneca Is Taking Steps to Improve Its Position in Oncology Sep 19 2016
    Roche Sees Soaring Revenue from Its Bladder Cancer Treatment Sep 16 2016
    What Investors Can Glean from GlaxoSmithKline’s Revenue Trend Sep 09 2016
    Is Johnson & Johnson’s Valuation High Compared to Its Peers? Aug 30 2016
    AstraZeneca’s Recent Product Developments Aug 25 2016
    AstraZeneca and Its Oncology Segment’s Growth in 2Q16 Aug 25 2016
    How Crestor Weakened AstraZeneca’s CVMD Segment in 2Q16 Aug 24 2016
    Remicade Is Driving Down Merck’s Immunology Franchise Aug 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)